MedTrace Logo

Intercostal Liposomal Bupivacaine for the Management of Blunt Chest Wall Trauma

NCT02749968 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2022-04-04

Study results available
· View outcomes & findings →

Summary

This is a study of liposomal bupivacaine for pain control in patients with blunt chest wall trauma.

Conditions

  • Blunt Chest Wall Trauma
  • Rib Fracture
  • Sternal Fracture

Interventions

DRUG

Liposomal bupivacaine

1 mL of liposomal bupivacaine injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position

DRUG

0.9% sodium chloride

1 mL of 0.9% saline injected with a 25-G needle just below each affected rib by the intercostal neurovascular bundle in a paraspinal position

Sponsors & Collaborators

  • United States Air Force

    collaborator FED

  • University of Cincinnati

    lead OTHER

Principal Investigators

  • Michael D Goodman, MD · Department of Surgery, University of Cincinnati

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-03-09
Primary Completion
2021-01-01
Completion
2021-01-01
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02749968 on ClinicalTrials.gov